PG
TBPH icon

PEAK6 Group’s Theravance Biopharma TBPH Stock Holding History

PEAK6 Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$159K Buy
+7,000
New +$166K ﹤0.01% 3479

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

PEAK6 Group's TBPH Position: Q2 2018 in Review

PEAK6 Group opened a new position in Theravance Biopharma (TBPH) in Q2 2018: 913 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #4069 among its holdings.

86 funds tracked by Wall St. Rank hold TBPH as of Q2 2018.

  • PEAK6 Group held 913 shares of Theravance Biopharma worth $21K as of Q2 2018.
  • Theravance Biopharma was a new PEAK6 Group position in Q2 2018.
  • Theravance Biopharma made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #4069 holding.
  • 86 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.